journal
MENU ▼
Read by QxMD icon Read
search

European Thyroid Journal

journal
https://www.readbyqxmd.com/read/30374432/thyroid-swelling-a-common-phenomenon-in-art
#1
Remo Accorona, Inge Huskens, Jeroen Meulemans, Carlo Cappelli, Piero Nicolai, Davide Lombardi
Representations of thyroid swelling, intended as an enlarged anterior neck region, in the artworks of various periods are sporadically reported in the scientific literature, and different intents may be hypothesized. A comprehensive review of the international literature was performed on PubMed, Embase, and ResearchGate with the aim to analyze the modalities of representation of thyroid swelling through the ages by different artistic movements. Thyroid swelling is frequently represented in the artworks of many stylistic periods and seems to be a known condition even by the earliest cultures...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30374431/bilateral-medullary-thyroid-carcinoma-in-a-3-year-old-female-patient-with-multiple-endocrine-neoplasia-2a-syndrome-undergoing-prophylactic-thyroidectomy-should-current-guidelines-be-revised
#2
Abbas Al-Kurd, David J Gross, David Zangen, Karine Atlan, Haggi Mazeh, Simona Grozinsky-Glasberg
Background: Multiple endocrine neoplasia (MEN) 2A is an autosomal dominant disorder that results from a mutation in the RET proto-oncogene on chromosome 10. Almost all of the affected patients develop medullary thyroid carcinoma (MTC). The American Thyroid Association recommends prophylactic thyroidectomy in MEN 2A pediatric patients, with the age of the recommended thyroidectomy varying according to the codon mutation present. Objectives: This report questions the reliability of the currently placed guidelines and whether the age threshold for prophylactic thyroidectomy in patients with known codon 634 mutations should be lowered, in parallel with an earlier evaluation of calcitonin levels in the serum...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30374430/well-differentiated-liposarcoma-localized-to-the-thyroid-gland
#3
Amruth R Palla, Craig Allen Bollig, Jeffrey Brian Jorgensen
Liposarcoma of the thyroid gland is a pathology that is rarely encountered in clinical practice, given the paucity of these cases. For the same reason, a definite treatment protocol has not been established for these cases. We present a case of a 49-year-old man who presented with a thyroid mass that was found to be a well-differentiated liposarcoma and was treated surgically with no adjuvant therapy other than close surveillance with clinical examination and MRI scans. On his most recent clinical visit, 9 months after surgery, there was no clinical or radiologic evidence of recurrence and the patient is doing well with good speech and swallow functions and no new symptoms...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30374429/are-papillary-thyroid-carcinomas-that-are-candidates-for-active-surveillance-in-fact-classical-microcarcinomas-restricted-to-the-gland
#4
Pedro Weslley Souza Rosario, Gabriela Franco Mourão, Pedro Henrique Lopes Oliveira, Tulio Henrique Silva
Background: Patients with small papillary thyroid carcinomas (PTC) can currently be maintained under active surveillance (AS). The recommended criteria are the following: adult individual, tumor ≤1 cm and not adjacent to the trachea or recurrent laryngeal nerve, cytology non-suggestive of the aggressive subtype, absence of lymph node (LN) involvement and extrathyroidal extension (ETE) on ultrasonography (US), and absence of clinical distant metastases. This study aimed to evaluate the frequency of the following peri- and postoperative findings in patients who met the criteria for PTC being candidate for AS: tumor > 1 cm, aggressive subtype or vascular invasion, ETE, clinical LN metastases (cN1), and distant metastases...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30374428/evaluation-of-the-role-of-braf-v600e-somatic-mutation-on-papillary-thyroid-cancer-disease-persistence-a-prospective-study
#5
Luca Damiani, Sabrina Lupo, Roberta Rossi, Stefania Bruni, Mirco Bartolomei, Stefano Panareo, Paola Franceschetti, Paolo Carcoforo, Giovanni Lanza, Stefano Pelucchi, Ettore Degli Uberti, Maria Chiara Zatelli
Background: BRAF V600E (c.1799T>A) somatic mutation evaluation in fine needle aspiration biopsies (FNAB) is a powerful diagnostic tool in the settings of papillary thyroid cancer (PTC). However, its prognostic value is still a matter of great debate and has been addressed mostly in retrospective studies. Objectives: To evaluate whether the somatic BRAF V600E mutation, assessed by direct sequencing in FNAB material of thyroid nodules, may correlate with disease persistence in PTC patients...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30374427/levothyroxine-liothyronine-combination-therapy-and-quality-of-life-is-it-all-about-weight-loss
#6
Luba Freja Michaelsson, Jeppe Lerche la Cour, Bjarke Borregaard Medici, Torquil Watt, Jens Faber, Birte Nygaard
Objectives: According to one hypothesis, the popularity of levothyroxine (L-T4 )/liothyronine (L-T3 ) combination therapy relates to weight loss. The purpose of this study was to detect a possible correlation between thyroid-related quality of life (QoL) and weight loss in hypothyroid patients switched from L-T4 monotherapy to L-T4 /L-T3 combination therapy. Methods: In an open-label cohort study, all hypothyroid patients referred to the University Hospital endocrine clinic due to persistent symptoms despite adequate L-T4 monotherapy (without other explanations for the symptoms) were switched from L-T4 monotherapy to L-T4 / L-T3 combination therapy at a ratio of approximately 17/1...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30374426/european-thyroid-association-eta-and-thyroid-federation-international-tfi-joint-position-statement-on-the-interchangeability-of-levothyroxine-products-in-eu-countries
#7
Eric Fliers, Barbara Demeneix, Ashok Bhaseen, Thomas H Brix
Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further investigation, the current position statement on behalf of both health-care providers and patients summarizes recent events in several European countries and provides a number of recommendations to limit the burden for patients, so as to prevent increased health-care consumption and health-care expenses in this context...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30374425/2018-european-thyroid-association-eta-guidelines-on-the-diagnosis-and-management-of-central-hypothyroidism
#8
Luca Persani, Georg Brabant, Mehul Dattani, Marco Bonomi, Ulla Feldt-Rasmussen, Eric Fliers, Annette Gruters, Dominique Maiter, Nadia Schoenmakers, A S Paul van Trotsenburg
Objectives: Central hypothyroidism (CeH) is a rare form of hypothyroidism characterized by insufficient thyroid stimulation due to disturbed pituitary and/or hypothalamic functioning. Due to its origin and the whole clinical context, CeH represents a challenging condition in clinical practice as it is characterized by suboptimal accuracy of clinical and biochemical parameters for diagnosis and management. Since no expert consensus or guidance for this condition is currently available, a task force of experts received the commitment from the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence...
October 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283741/low-dose-radioiodine-ablation-in-patients-with-low-risk-differentiated-thyroid-cancer
#9
Germán A Jimenez Londoño, Ana Maria Garcia Vicente, Julia Sastre Marcos, Francisco Jose Pena Pardo, Mariano Amo-Salas, Manuel Moreno Caballero, Maria Prado Talavera Rubio, Beatriz Gonzalez Garcia, Niletys Dafne Disotuar Ruiz, Angel Maria Soriano Castrejón
Aim: Based on the response criteria of the 2015 American Thyroid Associations guidelines, our objectives were to -determine the response rate when using a low dose of -131-I GBq in patients with low-risk differentiated thyroid cancer (LRDTC) and the influence of clinical and analytical variables on the prediction of complete response. Methods: We performed a multicentre and longitudinal study, including patients who were operated for LRDTC and who underwent radioiodine remnant ablation with a low-dose of 131-I...
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283740/prognostic-value-of-stimulated-thyroglobulin-levels-at-the-time-of-radioiodine-administration-in-differentiated-thyroid-cancer
#10
Mathieu Spaas, Brigitte Decallonne, Annouschka Laenen, Jaak Billen, Sandra Nuyts
Objective: The prognostic value of stimulated thyroglobulin (sTg) and Tg-related parameters prior to and immediately after radioactive iodine (RAI) administration was assessed in a cohort of patients presenting with differentiated thyroid cancer (DTC) as a predictor of recurrent or progressive structural disease. Methods: Clinical records of 180 DTC patients were retrospectively reviewed, and serum TSH, Tg, and Tg antibodies were recorded just before RAI administration (pre-) and at the time of whole body scanning (post-)...
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283739/can-suspicious-ultrasound-features-predict-brafv600e-status-in-papillary-thyroid-cancer
#11
Helmi Khadra, Ahmed Deniwar, Khuzema Mohsin, Dominique Monlezun, Emad Kandil
Background: Papillary thyroid carcinoma (PTC) can be predicted from certain suspicious ultrasound (US) features of thyroid nodules. The aim of this study was to examine if these suspicious features can predict the more aggressive PTC associated with B-type Raf kinase (BRAFV600E) mutation. Methods: This was a retrospective review of prospectively collected data on patients with PTC and known BRAFV600E status. All patients underwent preoperative US by the same surgeon who performed all the operations...
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283738/the-krakow-declaration-on-iodine-tasks-and-responsibilities-for-prevention-programs-targeting-iodine-deficiency-disorders
#12
REVIEW
(no author information available yet)
On April 18, 2018 the EUthyroid consortium released the Krakow Declaration on Iodine in response to the increasing concern about the deteriorating commitment of policymakers to address public health strategies against iodine deficiency disorders (IDD) in the European populations. Regulators and policymakers should harmonize obligatory Universal Salt Iodization to ensure free trade of fortified foodstuffs in Europe. Similarly, iodized animal feed requires regulatory approval to ensure free trade within the EU...
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283737/how-do-we-improve-the-impact-of-iodine-deficiency-disorders-prevention-in-europe-and-beyond
#13
Henry Völzke, Iris Erlund, Alicja Hubalewska-Dydejczyk, Till Ittermann, Robin P Peeters, Margaret Rayman, Monika Buchberger, Uwe Siebert, Betina H Thuesen, Michael B Zimmermann, Stefan Grünert, John H Lazarus
Background: Iodine deficiency disorders (IDD) represent a global health threat to individuals and societies. IDD prevention programmes have been introduced in many parts of the world. However, challenges remain, particularly in Europe due to fragmentation and diversity of approaches that are not harmonized. Objectives: This review is dedicated to the public-health impact of IDD prevention programmes. It sums up experiences collected by the EUthyroid consortium so far and provides information on stakeholders that should be involved in actions directed to improve the impact of IDD prevention...
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283736/thyroid-hemiagenesis-in-a-thyroiditis-prone-mouse-strain
#14
Sandra M McLachlan, Holly A Aliesky, Priscilla Garcia, Bianca Banuelos, Basil Rapoport
Background: Thyroid hemiagenesis, a rare congenital condition detected by ultrasound screening of the neck, is usually not manifested clinically in humans. This condition has been reported in mice with hypothyroidism associated with induced deficiency in paired box 8 and NK2 homeobox 1, sonic hedgehog, or T-box 1. Unexpectedly, we observed thyroid hemiagenesis in NOD.H2h4 mice, an unusual strain that spontaneously develops iodide enhanced thyroid autoimmunity but remains euthyroid. Objectives and Methods: First, to compare mice with thyroid hemiagenesis versus bilobed littermates for serum T4, autoantibodies to thyroglobulin (ELISA) and thyroid peroxidase (TPO; flow cytometry with eukaryotic cells expressing mouse TPO), gross anatomy, and thyroid histology; second, to estimate the percentage of mice with thyroid hemiagenesis in the NOD...
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283735/2018-european-thyroid-association-guideline-for-the-management-of-graves-hyperthyroidism
#15
George J Kahaly, Luigi Bartalena, Lazlo Hegedüs, Laurence Leenhardt, Kris Poppe, Simon H Pearce
Graves' disease (GD) is a systemic autoimmune disorder characterized by the infiltration of thyroid antigen-specific T cells into thyroid-stimulating hormone receptor (TSH-R)-expressing tissues. Stimulatory autoantibodies (Ab) in GD activate the TSH-R leading to thyroid hyperplasia and unregulated thyroid hormone production and secretion. Diagnosis of GD is straightforward in a patient with biochemically confirmed thyrotoxicosis, positive TSH-R-Ab, a hypervascular and hypoechoic thyroid gland (ultrasound), and associated orbitopathy...
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30283734/reflections-on-the-management-of-graves-hyperthyroidism
#16
EDITORIAL
Chantal Daumerie, Jacques Orgiazzi
No abstract text is available yet for this article.
August 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30023350/nodules-%C3%A2-1-cm-with-highly-suspicious-ultrasound-features-and-papillary-microcarcinoma-of-the-thyroid-is-fine-needle-aspiration-cytology-necessary-before-deciding-on-active-surveillance
#17
https://www.readbyqxmd.com/read/30023349/thyroid-gland-18-f-fdg-uptake-in-neurofibromatosis-type-1
#18
Zoë Y G J van Lierop, Sander Jentjens, Monique H M E Anten, Roel Wierts, Connie T Stumpel, Bas Havekes, Marinus J P G van Kroonenburgh
Purpose: To investigate thyroid gland characteristics on 18 F-FDG positron emission tomography/computed tomography (PET/CT) imaging in patients with neurofibromatosis type 1 (NF1). Subjects and Methods: Thyroid gland characteristics of patients with a clinical diagnosis of NF1 who underwent 18 F-FDG PET/CT imaging for the first time to distinguish benign neurofibroma from malignant peripheral nerve sheath tumor (MPNST) at our institution ( n = 69) were compared to PET/CT imaging of sarcoidosis ( n = 25) and early stage lung cancer (T1 N0 M0 tumors, n = 15) patients...
June 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30023348/successful-treatment-of-differentiated-thyroid-carcinoma-with-transaxillary-robotic-surgery-and-radioiodine-the-first-european-experience
#19
Marie Alix Balay, Patrick Aidan, Marie Helene Schlageter, Odette Georges, Taly Meas, Maroun Bechara, Marie Elisabeth Toubert, Isabelle Faugeron, Herve Monpeyssen, Cécile N Chougnet
Objectives: Transaxillary robotic thyroidectomy surgery (TARS) has been reported to be a safe approach in patients with differentiated thyroid carcinoma, and oncological responses are promising. Study Design: This study aimed to evaluate the oncological outcomes of TARS followed by radioiodine (RAI) therapy in patients with differentiated thyroid carcinoma. Between 2011 and 2016, patients treated for differentiated thyroid carcinoma by TARS in a single institution, followed by RAI, were retrospectively included...
June 2018: European Thyroid Journal
https://www.readbyqxmd.com/read/30023347/sorafenib-induced-acute-pancreatitis-in-a-patient-with-differentiated-thyroid-cancer
#20
Laura Ximena Kattah Martinez, Lisseth Fernanda Marín Carrillo, Leonardo Rojas Melo
Background: Sorafenib is a tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma, hepatocellular carcinoma, and recently for radioactive iodine (RAI)-refractory metastatic differentiated thyroid carcinoma (DTC). Several side effects have been described including alterations in amylase and lipase levels. Nonetheless, only a few cases of pancreatitis during renal carcinoma and hepatocellular carcinoma treatment have been described. Objective: To describe the first case report of sorafenib-induced acute pancreatitis during the treatment of thyroid carcinoma...
June 2018: European Thyroid Journal
journal
journal
47637
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"